5.03
-0.07 (-1.37%)
| Previous Close | 5.10 |
| Open | 5.09 |
| Volume | 450,828 |
| Avg. Volume (3M) | 2,072,856 |
| Market Cap | 1,527,062,784 |
| Price / Earnings (TTM) | 50.30 |
| Price / Earnings (Forward) | 30.77 |
| Price / Sales | 5.20 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | 9.66% |
| Operating Margin (TTM) | 28.74% |
| Diluted EPS (TTM) | 0.100 |
| Quarterly Revenue Growth (YOY) | 31.30% |
| Quarterly Earnings Growth (YOY) | 429.80% |
| Current Ratio (MRQ) | 3.28 |
| Operating Cash Flow (TTM) | 42.51 M |
| Levered Free Cash Flow (TTM) | 44.64 M |
| Return on Assets (TTM) | 9.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | MannKind Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.33 |
|
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.66% |
| % Held by Institutions | 55.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nitorum Capital, L.P. | 31 Dec 2024 | 8,747,316 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Mar 2025 | Announcement | MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 |
| 26 Feb 2025 | Announcement | MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 19 Feb 2025 | Announcement | MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 |
| 06 Feb 2025 | Announcement | MannKind to Present at Upcoming Investor Conferences |
| 06 Jan 2025 | Announcement | MannKind Expands Executive Leadership Team |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |